Our Story

Dr. Christopher Zoumalan

We heal scars better than them, and here's why.

Skinuva™ Scar was founded by Dr. Christopher Zoumalan, a Board-Certified Ophthalmic Plastic and Reconstructive Surgeon. Inspired by his passion for science and medicine, he dedicated the past several years researching wound-healing and identifying the best techniques to recover surgical scars in his patients that underwent surgery.

Unmet need in current topical scar therapy

Although there has been major medical advancements in surgical procedures to minimize scarring, patients are still faced with concerns of visible scars that remain post-surgery.

Since the introduction of silicone cream in the late 1990's there has been limited advancements in the topical scar therapy industry. Pertaining to the stagnate progress, Dr. Zoumalan and his team of scientists implemented medical literature and clinical data within their product development.

Watch this animation to see how Skinuva™ Scar is the most advanced scar cream yet to be formulated.
Skinuva Scar is the only scar cream that uses selective growth factors
Lack of advancements in scar creams for nearly 20 years until now
Lack of advancements in scar creams for nearly 20 years until now
Incredible results with Skinuva Scar

Patience in research and formulation were keys to success for Skinuva™ Scar

Selective ingredients such as specific Growth Factors were integrated within the formulation of Skinuva™ Scar to create what is now recognized as- one of the most advanced topical scar creams. Skinuva™ Scar is the first and only scar cream in the industry that uses selective Growth Factors in its formulation.

Scarless healing in fetuses: This knowledge was crucial in the development of Skinuva™ Scar

Scar free healing in fetuses occurs due to a complex upregulation and downregulation of certain growth factors. By utilizing such knowledge, Skinuva's team of scientists, clinicians, stem cell experts, and chemists formulated its first product in its Growth Factor Pipeline: Skinuva™ Scar.